Oliver Luxxe Assets LLC Purchases 14,447 Shares of CVS Health Corporation $CVS

Oliver Luxxe Assets LLC boosted its holdings in CVS Health Corporation (NYSE:CVS) by 16.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 103,446 shares of the pharmacy operator’s stock after acquiring an additional 14,447 shares during the quarter. CVS Health accounts for approximately 1.2% of Oliver Luxxe Assets LLC’s holdings, making the stock its 23rd largest position. Oliver Luxxe Assets LLC’s holdings in CVS Health were worth $8,209,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the business. Norges Bank purchased a new position in shares of CVS Health in the second quarter worth $1,358,698,000. Wellington Management Group LLP boosted its position in shares of CVS Health by 391.6% during the third quarter. Wellington Management Group LLP now owns 6,330,717 shares of the pharmacy operator’s stock valued at $477,273,000 after buying an additional 5,042,816 shares during the last quarter. Amundi increased its holdings in CVS Health by 95.3% in the 3rd quarter. Amundi now owns 7,453,980 shares of the pharmacy operator’s stock worth $572,665,000 after buying an additional 3,637,943 shares in the last quarter. Invesco Ltd. increased its holdings in CVS Health by 15.3% in the 2nd quarter. Invesco Ltd. now owns 23,532,479 shares of the pharmacy operator’s stock worth $1,623,270,000 after buying an additional 3,118,626 shares in the last quarter. Finally, Capital Research Global Investors raised its position in CVS Health by 24.5% in the 3rd quarter. Capital Research Global Investors now owns 11,469,250 shares of the pharmacy operator’s stock worth $864,667,000 after buying an additional 2,253,531 shares during the last quarter. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

CVS Health Stock Performance

CVS opened at $71.58 on Friday. The company’s 50 day moving average is $77.48 and its 200 day moving average is $77.81. The company has a current ratio of 0.84, a quick ratio of 0.63 and a debt-to-equity ratio of 0.80. The company has a market cap of $91.07 billion, a price-to-earnings ratio of 51.87, a PEG ratio of 0.75 and a beta of 0.49. CVS Health Corporation has a 12-month low of $58.35 and a 12-month high of $85.15.

CVS Health (NYSE:CVS) last announced its earnings results on Tuesday, February 10th. The pharmacy operator reported $1.09 EPS for the quarter, beating analysts’ consensus estimates of $1.00 by $0.09. The business had revenue of $105.69 billion during the quarter, compared to analysts’ expectations of $103.67 billion. CVS Health had a net margin of 0.44% and a return on equity of 11.31%. The firm’s revenue was up 8.2% on a year-over-year basis. During the same period in the prior year, the company earned $1.19 earnings per share. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. On average, equities research analysts predict that CVS Health Corporation will post 5.89 EPS for the current year.

CVS Health Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, May 4th. Investors of record on Thursday, April 23rd will be issued a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a yield of 3.7%. The ex-dividend date of this dividend is Thursday, April 23rd. CVS Health’s dividend payout ratio (DPR) is currently 192.75%.

Key CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS’s board declared a quarterly dividend of $0.665/share (payable May 4; record April 23), a cash-return signal that can support the share price. CVS Health declares quarterly dividend
• Positive Sentiment: Brokerages’ consensus rating sits at “Moderate Buy,” providing analyst support amid volatility. CVS Health Corporation (NYSE:CVS) Receives Consensus Rating of “Moderate Buy” from Brokerages
• Positive Sentiment: CVS announced a $2.24M investment to expand health access in west Charlotte — a community-health initiative that highlights growth of care-delivery and outreach programs. CVS Health invests $2.24 million in west Charlotte health initiative
• Neutral Sentiment: Media roundup and dividend-focused pieces are covering CVS alongside other dividend payers — keeps the name in income-focused investor conversations but is unlikely to move shares materially. Dividend roundup: JPMorgan Chase, Micron Technology, CVS Health, Broadcom, and more
• Neutral Sentiment: Coverage calling CVS a “trending” stock and roundups on healthcare stock picks keep investor attention but are mixed in tone — watch for conviction from earnings/forward guidance. CVS Health Corporation (CVS) Is a Trending Stock: Facts to Know Before Betting on It
• Neutral Sentiment: Company exec discussed AI policy and quality initiatives — signals operational focus but not an immediate catalyst. CVS Health/Aetna executive discusses company AI policy and the harder truth about quality
• Negative Sentiment: Bernstein Litowitz filed a racketeering class action against CaremarkPCS and CVS alleging fraud of PBM customers — this is a material legal overhang that could prompt costs, fines or settlements. Bernstein Litowitz Berger & Grossmann Announces Filing of Racketeering Class Action Against CaremarkPCS and CVS Health Corporation
• Negative Sentiment: Tennessee legislation targeting pharmacy benefit managers (PBMs) could force store closures — state estimates say 100+ CVS locations might be affected, raising local revenue and access risks. TN bill targeting pharmacy benefit managers could threaten closure of 100+ CVS stores in the state
• Negative Sentiment: Lawmakers and a U.S. Representative (Aftyn Behn) are calling for investigations and have heard conflicting testimony about CVS claims that pharmacies will close — increased regulatory scrutiny and political risk. Rep. Aftyn Behn calls for an investigation into CVS claims that pharmacies are closing
• Negative Sentiment: Local reporting and commentary examine whether lawmakers can curb CVS/PBM influence on drug pricing — signals broader regulatory attention on CVS’s PBM business. Could lawmakers crack CVS’s grip on the prescription drug supply chain?

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on CVS shares. Piper Sandler reaffirmed an “overweight” rating and set a $101.00 price target (up from $99.00) on shares of CVS Health in a report on Wednesday, December 10th. Leerink Partners reissued an “outperform” rating and set a $98.00 price objective on shares of CVS Health in a report on Thursday, March 5th. Cantor Fitzgerald restated an “overweight” rating on shares of CVS Health in a report on Wednesday, December 10th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of CVS Health in a research report on Monday, December 29th. Finally, Barclays increased their price target on CVS Health from $87.00 to $93.00 and gave the company an “overweight” rating in a report on Wednesday, December 10th. Twenty analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $95.05.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.